Published in Infect Immun on January 01, 1996
Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect Immun (1996) 2.18
Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect Immun (1998) 1.89
Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection. Am J Pathol (2001) 1.67
Interleukin-12 in infectious diseases. Clin Microbiol Rev (1997) 1.63
beta-Chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect Immun (1999) 1.44
Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria. PLoS Pathog (2006) 1.40
IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. PLoS Negl Trop Dis (2010) 1.37
Modulation of chemokine production and inflammatory responses in interferon-gamma- and tumor necrosis factor-R1-deficient mice during Trypanosoma cruzi infection. Am J Pathol (2001) 1.36
IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J Immunol (2010) 1.35
Interleukin-12-mediated resistance to Trypanosoma cruzi is dependent on tumor necrosis factor alpha and gamma interferon. Infect Immun (1996) 1.30
Interferon-gamma and tumor necrosis factor-alpha determine resistance to Paracoccidioides brasiliensis infection in mice. Am J Pathol (2000) 1.26
Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Semin Immunopathol (2012) 1.26
Intraphagosomal peroxynitrite as a macrophage-derived cytotoxin against internalized Trypanosoma cruzi: consequences for oxidative killing and role of microbial peroxiredoxins in infectivity. J Biol Chem (2010) 1.17
Gamma interferon modulates CD95 (Fas) and CD95 ligand (Fas-L) expression and nitric oxide-induced apoptosis during the acute phase of Trypanosoma cruzi infection: a possible role in immune response control. Infect Immun (1999) 1.17
Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob Agents Chemother (1998) 1.15
Trypanosoma cruzi infects human dendritic cells and prevents their maturation: inhibition of cytokines, HLA-DR, and costimulatory molecules. Infect Immun (1999) 1.12
Stage-dependent role of nitric oxide in control of Trypanosoma cruzi infection. Infect Immun (2001) 1.10
During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein. Infect Immun (2002) 1.09
Successive tick infestations selectively promote a T-helper 2 cytokine profile in mice. Immunology (1999) 1.08
Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas' disease morbidity? Clin Exp Immunol (2006) 1.08
Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi. Infect Immun (2011) 1.04
Contribution of NK, NK T, gamma delta T, and alpha beta T cells to the gamma interferon response required for liver protection against Trypanosoma cruzi. Infect Immun (2006) 1.02
Leukotriene B(4) induces nitric oxide synthesis in Trypanosoma cruzi-infected murine macrophages and mediates resistance to infection. Infect Immun (2002) 1.01
Pathogenesis of Chagas disease: time to move on. Front Biosci (Elite Ed) (2012) 1.01
The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi. Infect Immun (2006) 0.99
Platelet-activating factor induces nitric oxide synthesis in Trypanosoma cruzi-infected macrophages and mediates resistance to parasite infection in mice. Infect Immun (1999) 0.98
CD40 ligation prevents Trypanosoma cruzi infection through interleukin-12 upregulation. Infect Immun (1999) 0.97
Activation of natural killer T cells by alpha-galactosylceramide impairs DNA vaccine-induced protective immunity against Trypanosoma cruzi. Infect Immun (2003) 0.97
Role of SOCS2 in modulating heart damage and function in a murine model of acute Chagas disease. Am J Pathol (2012) 0.96
NK cells contribute to the control of Trypanosoma cruzi infection by killing free parasites by perforin-independent mechanisms. Infect Immun (2004) 0.94
NLRP3 controls Trypanosoma cruzi infection through a caspase-1-dependent IL-1R-independent NO production. PLoS Negl Trop Dis (2013) 0.94
Evidence for a perforin-mediated mechanism controlling cardiac inflammation in Trypanosoma cruzi infection. Int J Exp Pathol (2002) 0.91
Gene gun-mediated delivery of an interleukin-12 expression plasmid protects against infections with the intracellular protozoan parasites Leishmania major and Trypanosoma cruzi in mice. Immunology (2000) 0.90
Fas ligand-dependent inflammatory regulation in acute myocarditis induced by Trypanosoma cruzi infection. Am J Pathol (2007) 0.90
Circulating levels of cyclooxygenase metabolites in experimental Trypanosoma cruzi infections. Mediators Inflamm (2004) 0.88
Critical contribution of CD28-CD80/CD86 costimulatory pathway to protection from Trypanosoma cruzi infection. Infect Immun (2003) 0.88
Role of IFN-alpha/beta and IL-12 in the activation of natural killer cells and interferon-gamma production during experimental infection with Trypanosoma cruzi. Clin Exp Immunol (2003) 0.88
In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors. Br J Pharmacol (2007) 0.87
NFATc1 mediates Toll-like receptor-independent innate immune responses during Trypanosoma cruzi infection. PLoS Pathog (2009) 0.86
NLR proteins and parasitic disease. Immunol Res (2014) 0.86
Enhancement of natural killer (NK) cell cytotoxicity and induction of NK cell-derived interferon-gamma (IFN-gamma) display different kinetics during experimental infection with Trypanosoma cruzi. Clin Exp Immunol (2000) 0.86
Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors. Antimicrob Agents Chemother (2009) 0.86
Differential use of TLR2 and TLR9 in the regulation of immune responses during the infection with Trypanosoma cruzi. PLoS One (2013) 0.86
IL-10-IFN-γ double producers CD4+ T cells are induced by immunization with an amastigote stage specific derived recombinant protein of Trypanosoma cruzi. Int J Biol Sci (2011) 0.83
Chagas disease: still many unsolved issues. Mediators Inflamm (2014) 0.82
During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment. Immunology (2006) 0.81
CD40 and the immune response to parasitic infections. Semin Immunol (2009) 0.81
Nonspecific immune responses and mechanisms of resistance to Eimeria papillata infections in mice. Infect Immun (1997) 0.80
Administration of a nondepleting anti-CD25 monoclonal antibody reduces disease severity in mice infected with Trypanosoma cruzi. Eur J Microbiol Immunol (Bp) (2014) 0.80
Interaction of natural killer cells with Trypanosoma cruzi-infected fibroblasts. Clin Exp Immunol (2006) 0.80
Humoral and cellular immune responses in BALB/c and C57BL/6 mice immunized with cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens, in acute experimental Trypanosoma cruzi infection. Parasitol Res (2005) 0.80
Nutritional Status Driving Infection by Trypanosoma cruzi: Lessons from Experimental Animals. J Trop Med (2011) 0.80
The quantitative and functional changes of NK cells in mice infected with Angiostrongylus cantonensis. Parasitol Res (2014) 0.79
Modulation of B-lymphocyte and NK cell activities by glycoinositolphospholipid purified from Trypanosoma cruzi. Infect Immun (1999) 0.79
Trypanosoma cruzi infection in genetically selected mouse lines: genetic linkage with quantitative trait locus controlling antibody response. Mediators Inflamm (2014) 0.78
Induction of IL-12 production in human peripheral monocytes by Trypanosoma cruzi Is mediated by glycosylphosphatidylinositol-anchored mucin-like glycoproteins and potentiated by IFN- γ and CD40-CD40L interactions. Mediators Inflamm (2014) 0.78
Immunity and immune modulation in Trypanosoma cruzi infection. Pathog Dis (2015) 0.78
Mast cell function and death in Trypanosoma cruzi infection. Am J Pathol (2011) 0.78
Natural killer T cells are required for the development of a superantigen-driven T helper type 2 immune response in mice. Immunology (2005) 0.78
Escaping Deleterious Immune Response in Their Hosts: Lessons from Trypanosomatids. Front Immunol (2016) 0.76
The Ly49E Receptor Inhibits the Immune Control of Acute Trypanosoma cruzi Infection. Front Immunol (2016) 0.75
Immune complexes in chronic Chagas disease patients are formed by exovesicles from Trypanosoma cruzi carrying the conserved MASP N-terminal region. Sci Rep (2017) 0.75
Ebi3 Prevents Trypanosoma cruzi-Induced Myocarditis by Dampening IFN-γ-Driven Inflammation. Front Immunol (2017) 0.75
A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol (1973) 45.44
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 19.80
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 10.60
Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 7.52
Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A (1993) 6.87
Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci U S A (1993) 6.33
Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med (1993) 5.75
Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med (1991) 5.04
Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A (1991) 4.95
Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. J Immunol (1989) 4.70
Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol (1991) 4.69
Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med (1993) 4.49
Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli. Infect Immun (1991) 4.18
Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol (1990) 3.79
Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma (1984) 3.68
Early gamma interferon production by natural killer cells is important in defense against murine listeriosis. Infect Immun (1991) 3.59
Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature (1992) 3.50
Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunol Rev (1991) 3.49
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med (1992) 3.34
Toxoplasma gondii induces a T-independent IFN-gamma response in natural killer cells that requires both adherent accessory cells and tumor necrosis factor-alpha. J Immunol (1993) 3.25
Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J Exp Med (1994) 3.02
The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. Eur J Immunol (1992) 2.98
Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay. J Immunol (1990) 2.79
Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp Med (1991) 2.68
In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol (1988) 2.59
Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun (1994) 2.35
Protective effects of specific antibodies in Trypanosoma cruzi infections. J Immunol (1976) 2.20
Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol (1994) 2.11
The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp Parasitol (1989) 1.79
Salmonella typhimurium induces IFN-gamma production in murine splenocytes. Role of natural killer cells and macrophages. J Immunol (1993) 1.73
IL-10 mediates susceptibility to Trypanosoma cruzi infection. J Immunol (1994) 1.70
Suppressor cells present in the spleens of Trypanosoma cruzi-infected mice. J Immunol (1979) 1.70
Enhancing effects of gamma interferon on phagocytic cell association with and killing of Trypanosoma cruzi. Infect Immun (1985) 1.62
Differential susceptibilities of mice genomically deleted of CD4 and CD8 to infections with Trypanosoma cruzi or Trypanosoma brucei. Infect Immun (1993) 1.59
Synergistic protection by specific antibodies and interferon against infection by Trypanosoma cruzi in vitro. Eur J Immunol (1984) 1.58
Restoration of in vitro immune responses of spleen cells from mice infected with Trypanosoma cruzi by supernatants containing interleukin 2. J Immunol (1984) 1.53
Lymphokine-activated killer cells, natural killer cells and cytokines. Curr Opin Immunol (1991) 1.47
Suppressed antibody responses to sheep erythrocytes in mice with chronic Trypanosoma cruzi infections are restored with interleukin 2. J Immunol (1984) 1.45
Xid-associated resistance to experimental Chagas' disease is IFN-gamma dependent. J Immunol (1993) 1.38
Parasitic load increases and myocardial inflammation decreases in Trypanosoma cruzi-infected mice after inactivation of helper T cells. Ann Inst Pasteur Immunol (1988) 1.27
Infection with Leishmania major induces interleukin-12 production in vivo. Immunol Lett (1994) 1.26
Role of T helper/inducer cells as well as natural killer cells in resistance to Trypanosoma cruzi infection. Scand J Immunol (1988) 1.18
Immune deficiency in chronic Trypanosoma cruzi infection. Recombinant IL-1 restores Th function for antibody production. J Immunol (1989) 1.17
Differential control of IFN-gamma and IL-2 production during Trypanosoma cruzi infection. J Immunol (1991) 1.12
Recombinant granulocyte-macrophage colony-stimulating factor restores deficient immune responses in mice with chronic Trypanosoma cruzi infections. J Immunol (1990) 1.12
Endogenous interferon-gamma, macrophage activation, and murine host defense against acute infection with Trypanosoma cruzi. J Infect Dis (1991) 1.08
Trypanosoma cruzi: maintenance of parasite-specific T cell responses in lymph nodes during the acute phase of the infection. Exp Parasitol (1990) 0.99
Modulation of both interleukin 2 receptor expression and interleukin 2 production during experimental murine Trypanosoma cruzi infection. Scand J Immunol (1989) 0.94
Lymphoblast transformation as a measure of immune competence during experimental Chagas' disease. J Parasitol (1980) 0.90
Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg (1984) 3.96
Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science (1992) 3.71
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest (1985) 3.41
Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A (1993) 3.40
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med (1992) 3.34
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis (1996) 2.93
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp Med (1991) 2.68
A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci U S A (2005) 2.53
Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol (1995) 2.37
Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun (1994) 2.35
Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med (1989) 2.30
Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol (1994) 2.25
Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect Immun (1996) 2.18
CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity (1996) 2.11
Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J Exp Med (1998) 2.06
Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res (2000) 1.98
Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun (1999) 1.95
Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg (1986) 1.93
rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection. Clin Diagn Lab Immunol (1998) 1.90
Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis (1987) 1.87
P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol (2001) 1.86
Murine thymocytes proliferate in direct response to interleukin-7. Blood (1989) 1.86
Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. Circulation (2000) 1.82
A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med (1995) 1.81
T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol (2000) 1.76
Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A (1993) 1.76
Tool support for authoring eligibility criteria for cancer trials. Proc AMIA Symp (1999) 1.73
IL-10 mediates susceptibility to Trypanosoma cruzi infection. J Immunol (1994) 1.70
IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol (1995) 1.69
Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn (2001) 1.67
Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J Clin Microbiol (2000) 1.66
Immunopathology of experimental cutaneous leishmaniasis. Am J Pathol (1984) 1.65
Chemokines in oral inflammatory diseases: apical periodontitis and periodontal disease. J Dent Res (2007) 1.65
Modulation of mucosal immunity in a murine model of food-induced intestinal inflammation. Clin Exp Allergy (2007) 1.65
Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-gamma as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi. Microbes Infect (2000) 1.63
Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J Exp Med (2000) 1.60
Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun (1999) 1.55
Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report. Braz J Infect Dis (2001) 1.54
Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol (2001) 1.54
Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun (1998) 1.53
Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope (2000) 1.51
Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun (2001) 1.51
Regulation of T cell proliferation by IL-7. J Immunol (1990) 1.50
IL-10 is induced during HIV-1 infection and is capable of decreasing viral replication in human macrophages. J Immunol (1994) 1.46
Evidence of the presence of T helper type 17 cells in chronic lesions of human periodontal disease. Oral Microbiol Immunol (2009) 1.45
Suppressed antibody responses to sheep erythrocytes in mice with chronic Trypanosoma cruzi infections are restored with interleukin 2. J Immunol (1984) 1.45
beta-Chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect Immun (1999) 1.44
Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis. J Clin Microbiol (2000) 1.44
A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis (1998) 1.43
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg (1997) 1.43
Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors. Oral Microbiol Immunol (2006) 1.40
The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol (2009) 1.39
Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis. J Immunol (1998) 1.38
Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol (1999) 1.38
Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg (1990) 1.37
Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients. J Exp Med (1992) 1.37
Modulation of chemokine production and inflammatory responses in interferon-gamma- and tumor necrosis factor-R1-deficient mice during Trypanosoma cruzi infection. Am J Pathol (2001) 1.36
Heterologous antibody responses in mice with chronic T. cruzi infection: depressed T helper function restored with supernatants containing interleukin 2. J Immunol (1984) 1.35
Identification and synthesis of a major conserved antigenic epitope of Trypanosoma cruzi. Proc Natl Acad Sci U S A (1992) 1.34
The dual role of p55 tumour necrosis factor-alpha receptor in Actinobacillus actinomycetemcomitans-induced experimental periodontitis: host protection and tissue destruction. Clin Exp Immunol (2007) 1.32
Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological forms of two Leishmania species. Am J Trop Med Hyg (1983) 1.32
Identification of specific and cross-reactive antigens of Leishmania donovani chagasi by human infection sera. J Immunol (1987) 1.32
Mycobacterium tuberculosis-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction. J Immunol (2000) 1.31
LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol (1998) 1.31
Suppression of cell-mediated immunity in experimental Chagas' disease. Z Parasitenkd (1977) 1.30
Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis. Infect Immun (1998) 1.28
Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin. Trans R Soc Trop Med Hyg (1995) 1.27
Interferon-gamma and tumor necrosis factor-alpha determine resistance to Paracoccidioides brasiliensis infection in mice. Am J Pathol (2000) 1.26
A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera. J Infect Dis (1999) 1.25
Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun (2002) 1.25
Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol (1996) 1.24
Evaluation of the micro enzyme-linked immunosorbent assay (ELISA) for antibodies in American visceral leishmaniasis: antigen selection for detection of infection-specific responses. Am J Trop Med Hyg (1986) 1.24
A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. Br J Pharmacol (2009) 1.23
Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. II. Treatment by intrahepatic chemotherapy. Ann Surg (1984) 1.23
Anti-CD4 abrogates rejection and reestablishes long-term tolerance to syngeneic newborn hearts grafted in mice chronically infected with Trypanosoma cruzi. J Exp Med (1992) 1.20
Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun (1995) 1.20
Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J Immunol (1998) 1.19
Functional activities of rosette separated human peripheral blood leukocytes. J Immunol (1975) 1.19
Spleen cell-mediated suppression of IgG production to a non-parasite antigen during chronic Trypanosoma cruzi infection in mice. J Immunol (1983) 1.18
Gamma interferon modulates CD95 (Fas) and CD95 ligand (Fas-L) expression and nitric oxide-induced apoptosis during the acute phase of Trypanosoma cruzi infection: a possible role in immune response control. Infect Immun (1999) 1.17
Molecular karyotype of species and subspecies of Leishmania. Mol Biochem Parasitol (1986) 1.17
Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol (2001) 1.16
Serological expression cloning and immunological evaluation of MTB48, a novel Mycobacterium tuberculosis antigen. J Clin Microbiol (2001) 1.15
Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species. J Infect Dis (1993) 1.15
Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol (1995) 1.15
Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene (2000) 1.14
Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res (2001) 1.12
Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol (1991) 1.12
Nitric oxide-induced apoptotic cell death in the acute phase of Trypanosoma cruzi infection in mice. Immunol Lett (1998) 1.12
Tumour necrosis factor-alpha and leukotriene B(4) mediate the neutrophil migration in immune inflammation. Br J Pharmacol (2001) 1.12
Periodontitis and arthritis interaction in mice involves a shared hyper-inflammatory genotype and functional immunological interferences. Genes Immun (2010) 1.11
Failure to provide clinicians useful IT systems: opportunities to leapfrog current technologies. Methods Inf Med (2008) 1.11
Leishmania gp63 molecule implicated in cellular adhesion lacks an Arg-Gly-Asp sequence. Mol Biochem Parasitol (1990) 1.10
Serodiagnosis of human granulocytic ehrlichiosis by using novel combinations of immunoreactive recombinant proteins. J Clin Microbiol (2001) 1.10
In vitro human reactivity to staphylococcal phage lysate. J Immunol (1975) 1.09
Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol (1991) 1.09